Drugs / NBI-1065846
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05165394 | Nov 2021 → Jul 2023 | atypical depressive disorder, major depressive disorder | Neurocrine Biosciences | Completed | Missed primary |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NBI-1065846 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05165394 ↗ |